EGFR and lung cancer: However, it is presently impossible to ascertain the clinical prevalence of single-agent MET dependency in EGFR-mutant lung cancer, because genotyping of lung cancers is most often based on DNA sequencing, which would not capture diminished expression of the mutant EGFR allele.